NERVGEN PHARMA CORP.
For the period ended Aug 13, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Aug 13, 2026 · Filed Aug 13, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.3 · Phase 3 RESTORE Study Update
Phase 3 RESTORE Study Update
In April 2026, NervGen announced alignment with the FDA on the clinical trial design of RESTORE, the Company’s Phase 3 registrational study of NVG-291 in individuals with chronic SCI. Since then, NervGen has expanded its clinical development and operations team and has completed several key start-up activities, including finalizing site selection which has prioritized neurorehabilitation hospitals and clinics in the United States and Canada that specialize in the treatment of individuals with SCI.
NervGen is advancing a coordinated site activation strategy for RESTORE and expects to begin screening in September 2026, with the first participant anticipated to be dosed shortly thereafter. Additional sites are expected to be activated on a rolling basis. The Company continues to expect completion of enrollment in 2H 2027, with anticipated topline data readout in 1H 2028.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.